AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : O. L. Chinot , T. de La Motte Rouge , N. Moore , A. Zeaiter , A. Das , H. Phillips , Z. Modrusan , T. Cloughesy
- چاپ و سال / کشور: 2011
Description
Despite treatment with the current standardof- care therapies, patients with newly diagnosed glioblastoma multiforme (GBM) exhibit dismal prognoses. Bevacizumab has demonstrated activity in patients with recurrent GBM and phase 2 trials indicate that the combination of bevacizumab with standard-of-care therapy is feasible and active for patients with newly diagnosed GBM. Bevacizumab has been granted US approval for use as single-agent therapy for patients with progressive GBM following prior therapy, although it has not received approval for use in patients with GBM in Europe. Phase 3 studies have been initiated in patients with newly diagnosed GBM and are currently recruiting patients. We describe the protocol for the AVAglio phase 3 registration trial, which is designed to evaluate the efficacy and safety of combining bevacizumab with standard-of-care therapy in patients with newly diagnosed GBM.
Adv Ther (2011) 28(4):334-340. Received: August 4, 2010 / Published online: March 14, 2011
